MRI Based Biomarkers in Pediatric Autoimmune Liver Disease
Key facts
- Who runs it
- Children's Hospital Medical Center, Cincinnati
- Where
- Cincinnati, United StatesSee the site
- Trial code
- Status
- Recruiting
- People taking part
- 115 people, planned
- Started
- 17 Jan 2017
- Expected to end
- 30 Jan 2030
- Type of study
- Observational
- Record updated
- 19 August 2026
Who can take part
- Age
- 6 years to 23 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (10)Hide the full registry criteria
Who can take part
- Age 6-23 years old
- Established or suspected clinical diagnosis of AIH or PSC
Who cannot take part
- Absolute contraindication for MRI (e.g. pacemaker, metallic implants, claustrophobia)
- History of liver transplantation
- Chronic Hepatitis B or untreated hepatitis C virus infection
- Diagnosis of cardiac hepatopathy
- Diagnosis of Wilson's disease, Alpha-1 Antitrypsin deficiency, or Glycogen storage disease
- Skin conditions which could be aggravated by MREL (i.e. Epidermolysis bullosa)
- Pregnancy
- Diagnosis of cystic fibrosis or biliary atresia
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Autoimmune liver disease or primary sclerosing cholangitis or autoimmune hepatitis
This trial is currently available in United States.
- Cincinnati Childrens Hospital Medical CenterCincinnati, United StatesContact: Alexander Miethke, MDTaking people
About the trial
What the trial wants to find out
Autoimmune liver diseases (AILD), which include Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) are a common etiological factors for chronic liver disease among adolescents. In all these conditions, autoimmune lymphocyte responses are thought to orchestrate inflammatory injury against hepatocytes (primarily in AIH) or cholangiocytes (in PSC). In this proposal we aim to evaluate the Magnetic Resonance Imaging (MRI) modalities; MR cholangiopancreatography (MRCP) and MR elastography (MREL), as non-invasive biomarkers to assess two primary pathophysiological processes of AILD: bile duct damage and liver fibrosis. In this cross-sectional study MRI based findings of bile duct injury and liver fibrosis will be correlated with both liver histology and circulating biomarkers of these disease processes.
The group in the trial
- Patients with autoimmune liver disease
Patients (6-23 y.o.) with established clinical diagnosis of AIH or suspected diagnosis of AIH based on elevated serum AST or ALT, elevated IgG level \>1.1 ULN, elevated titer of autoantibodies, including ANA, SMA, LKM, LC-1 or SLA, which is consistent with the simplified criteria for the diagnosis of AIH in children will be enrolled. Patients (6-23 y.o.) with established clinical diagnosis of PSC or Suspected diagnosis of PSC supported by abnormal cholangiogram (ERCP or MRCP) or elevated GGT\>1.5 ULN and dilated bile ducts by liver ultrasound will be enrolled.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Cross-sectional Study for Assessment of MRI Based Biomarkers of Bile Duct Injury and Hepatic Fibrosis in Pediatric Onset Autoimmune Liver Disease
- Criteria questions
- Built from NCT03175471, who can take part
- Publications
- Association Between MR Elastography Liver Stiffness and Histologic Liver Fibrosis in Children and Young Adults With Autoimmune Liver Disease.AJR. American journal of roentgenology, 2024
- Associations Between Quantitative MRI Metrics and Clinical Risk Scores in Children and Young Adults With Autoimmune Liver Disease.AJR. American journal of roentgenology, 2022
- Record updated
- 19 August 2026